SB414 6%
DrugTwice daily
Other names: NVN1000
NCT Number: NCT03445013
The objectives of this study are to assess the pharmacokinetics, pharmacodynamics, safety, and tolerability of SB414 in subjects with mild to moderate plaque psoriasis.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 1
Novella Site# 247, Boise, Idaho, United States
This is a phase 1b, multi-center, double-blind, randomized, vehicle-controlled study to be conducted in approximately 36 adult subjects with mild to moderate chronic plaque psoriasis. After obtaining informed consent, subjects will be randomized to active or vehicle treatment arms. Subjects will apply the study product (SB414 6% or Vehicle cream) twice daily to all affected areas of psoriasis on the trunk and/or extremities for 4 weeks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Twice daily
Other names: NVN1000
Vehicle Comparator
Other names: Placebo
Time frame: Day 29
Peak plasma concentrations of hMAP3 after topical application of SB414
Time frame: Day 29
Reported Adverse Events
Time frame: Baseline, Week 2 and Week 4
Subject-reported from 5-point tolerability scale overall presence and degree of itching and burning/stinging
Time frame: Baseline, Week 2 and Week 4
Target Plaque Severity Score will be collected
Time frame: Day 29
Change in relevant Pre and Post-dose tissue cytokine levels (mg/mg tissue)
Time frame: Screening, Baseline, Week 2 and Week 4
Physician's Static Global Assessment based on overall evaluation of the disease severity
Time frame: Screening, Baseline, Week 2 and Week 4
Itching due to psoriasis as reported by subject on a 11-point rating scale
Novan, Inc.
Industry
A Phase 1b Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study Assessing the PK, Pharmacodynamics, Safety, and Tolerability of SB414 in Subjects With Psoriasis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04728165
Psoriasis, Skin Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT01778569
Cardiovascular Disease, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT05295979
Psoriasis, Skin Diseases
Hong Kong
View Trial DetailsNCT07712731
Psoriasis, Skin Diseases
Baotou, China
View Trial Details